192725-17-0 Lopinavir AKSci E314
 
 
Loading Please Wait...
  E314    AKSci Reference Standard
Lopinavir
, 98% (HPLC)
 
ABT-378




IDENTITY
CAS Number:192725-17-0
MDL Number:MFCD22628840
MF:C37H48N4O5
MW:628.80
SPECIFICATIONS & PROPERTIES
Purity:98% (HPLC)
Spectra:FT-IR, LCMS, HPLC
Physical Form:White to off-white solid or crystalline powder
Melting Point:113-118°C
Long-Term Storage:Store long-term at 2-8°C

BIOLOGICAL INFO
Solubility:DMSO: 126mg/mL; H2O: <1mg/mL; EtOH: 126mg/mL
Application(s):HIV protease inhibitor
Form:Free Base

REVIEW

 An antiretroviral of the protease inhibitor class. It is used as a fixed-dose combination with another protease inhibitor, ritonavir.

REFERENCES
[1]Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, Asmelash A, Rassool M, Kimaiyo S, Shaffer D, Hosseinipour M, Mohapi L, Ssali F, Chibowa M, Amod F, Halvas E, Hogg E, Alston-Smith B, Smith L, Schooley R, Mellors J, Currier J; OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE Study Team (2012). Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med. 9(6):e1001236. PMID 22719231.
[2] Simpson KN, Baran RW, Collomb D, Beck EJ, Van de Steen O, Dietz B (2012). Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-na?ve and -experienced United Kingdom patients in 2011. J Med Econ. 15(4):796-806. PMID 22563716.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of July 15, 2019

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS

CATEGORIES

 APIs and Bioactives > Antivirals, HIV Protease Inhibitors


PubChem